Clin2
NCT06199895Possibly a fitRecruiting

Study of paclitaxel for patients with taxane-resistant solid tumors

Pancreatic AdenocarcinomaCholangiocarcinomaLung CancerStomach CancerEsophageal CarcinomaBreast Cancer

Treatments studied

Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.

This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
25 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have advanced cancer of the pancreas, bile ducts, lung, stomach, esophagus, or breast with a measurable tumor
  • Your cancer has become resistant to a taxane drug (like paclitaxel or docetaxel), meaning it didn’t shrink or came back after treatment
  • You are in generally good health (able to care for yourself, up and about more than half the day)
  • Your blood counts and liver/kidney function are within certain safe limits
  • You are not pregnant and agree to use effective birth control during the study and for 6 months after

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06765590Recruiting
Paclitaxel (albumin-bound) bioequivalence study in breast cancer

This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.

Luoyang, Henan
NCT06496724Recruiting
Study of albumin-bound paclitaxel combo for advanced breast cancer

This study tests a combination of two medicines (albumin-bound paclitaxel and a granulocyte-based therapy) for women with breast cancer that has come back or spread. It may be an option if you have already tried standard treatment and are looking for another approach.

Nanjing, Jiangsu
NCT05183126Recruiting· Phase 4
Paclitaxel dose study using a 1-hour muscle-area infusion

This trial studies how paclitaxel (a chemotherapy medicine) behaves in the body when given by a specific 1-hour infusion approach. It may help refine dosing for people with cancer using measurements from scans, and it includes a medicine schedule you must match.

Ann Arbor, Michigan
NCT07441486Not yet recruiting· Phase 2
Entinostat and oral paclitaxel for advanced breast cancer

This trial tests a combination of two drugs, entinostat and a pill form of paclitaxel, for people with a type of advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if you have already tried several treatments, including hormone therapy with a CDK4/6 inhibitor and a chemotherapy with paclitaxel.

NCT06752811Recruiting· Phase 3
Testing a new paclitaxel formula for advanced pancreatic cancer

This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.

Nanjing, Jiangsu
NCT04778839Recruiting· Phase 1
Paclitaxel drug in tiny “micelles” for advanced solid cancers

This Phase 1 trial tests a chemotherapy drug called paclitaxel in a special “micelle” form in people with advanced solid tumors. It’s mainly designed to check safety and dosing, and it may help shrink tumors in people who don’t have good standard treatment options.

Hanzhou, Zhejiang

Hear when a new Pancreatic Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.